Healthcare

Gilead’s New Acquisition Represents Critical Step in Cancer Treatment

Yesterday, Gilead Sciences (GILD) announced a major aquisition that brings further optimism to an already promising breast cancer drug. In a mission to bolster its oncology treatment portfolio, the biopharmaceutical company reports a huge move to acquire Immunomedics (IMMU), which will include the company’s promising breast cancer treatment drug Trodelvy. As an antibody-drug conjugate, Trodelvy

Read More ›

AstraZeneca Forced to Halt Testing the World’s “Leading” Vaccine Candidate

Touted as the world’s leading candidate to become approved for a COVID-19 vaccine, AstraZeneca’s (AZN) AZD1222 candidate, otherwise known as the “Oxford vaccine” has led to multiple agreements with the U.K., the U.S., Brazil and Australia. AstraZeneca is currently in phase 3 clinical trials, testing its AZD1222 vaccine with thousands of people around the world. But

Read More ›

As CDC Plans to Distribute Vaccine by Late October, Which Biotechs Are Leading the Race?

Last week a Financial Times article, cited three people briefed on a plan from President Trump’s administration to fast-track an experimental coronavirus vaccine from AstraZeneca (AZN), for “emergency use authorization.” This story, coupled with last Sunday’s announcement that the FDA will authorize the use of blood plasma from patients who have recovered from COVID-19 as

Read More ›

Could the Approaching Election Fast-Track a COVID-19 Vaccine?

Yesterday, a Financial Times article, cited three people briefed on a plan from President Trump’s administration to fast-track an experimental coronavirus vaccine from AstraZeneca (AZN), for “emergency use authorization.” The details of such a plan weren’t made available but it was understood its a course of action that would take place before the upcoming presidential

Read More ›

Astrazeneca Secures Another Deal for Its “World Leading” Vaccine Candidate

Touted as the world’s leading candidate to become approved for a COVID-19 vaccine, today, AstraZeneca (AZN) announced yet another deal the company has stuck up for it’s “Oxford vaccine.” This latest deal for Astrazencea will allow Australia to produce and distribute doses of the vaccine for its population of 25 million. Australian prime minister Scott

Read More ›

Market Overview